Amneal Pharmaceuticals, Inc Class A Common Stock (AMRX) had its best year since 2010 in 2023, returning 196.1%.

ASSET	YEAR	% RETURN
Amneal Pharmaceuticals, Inc Class A Common Stock (AMRX)	2010	44.05%
Amneal Pharmaceuticals, Inc Class A Common Stock (AMRX)	2011	-1.22%
Amneal Pharmaceuticals, Inc Class A Common Stock (AMRX)	2012	-0.87%
Amneal Pharmaceuticals, Inc Class A Common Stock (AMRX)	2013	20.11%
Amneal Pharmaceuticals, Inc Class A Common Stock (AMRX)	2014	26.11%
Amneal Pharmaceuticals, Inc Class A Common Stock (AMRX)	2015	33.71%
Amneal Pharmaceuticals, Inc Class A Common Stock (AMRX)	2016	-68.4%
Amneal Pharmaceuticals, Inc Class A Common Stock (AMRX)	2017	23.33%
Amneal Pharmaceuticals, Inc Class A Common Stock (AMRX)	2018	-18.98%
Amneal Pharmaceuticals, Inc Class A Common Stock (AMRX)	2019	-63.84%
Amneal Pharmaceuticals, Inc Class A Common Stock (AMRX)	2020	-8.23%
Amneal Pharmaceuticals, Inc Class A Common Stock (AMRX)	2021	2.79%
Amneal Pharmaceuticals, Inc Class A Common Stock (AMRX)	2022	-58.88%
Amneal Pharmaceuticals, Inc Class A Common Stock (AMRX)	2023	196.1%
Amneal Pharmaceuticals, Inc Class A Common Stock (AMRX)	2024	29.62%
Amneal Pharmaceuticals, Inc Class A Common Stock (AMRX)	2025	62.42%